Why insider trading matters?

Numerous studies have examined whether there is evidence that U.S. insiders systematically trade on private information despite the legal deterrence. The consensus appears to be that insider purchases (but not sales) tend to be followed by positive abnormal stock price performance, particularly for small growth stocks.

- Prof. B. Espen Eckbo, Dartmouth College
EYEGATE PHARMACEUTICALS INC (EYEG)
Sector: Healthcare; Industry: Biotechnology

EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye in the United States. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. It is also developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients and anterior uveitis; and Eyegate II drug delivery system. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-01-06 ARMISTICE CAPITAL, LLC 10%-Owner, Director Buy 1,531,101 $5.22 $8,000,003 Yes
2020-02-10 ARMISTICE CAPITAL, LLC 10%-Owner, Director Buy 23,000 $6.11 $140,460 No
2019-12-06 GOLDBERG MORTON Director Sell 1,961 $6.93 $13,590 No
2019-11-12 GOLDBERG MORTON Director Sell 2,001 $4.29 $8,584 No
2019-09-30 ARMISTICE CAPITAL, LLC 10%-Owner, Director Buy 605,001 $3.12 $1,890,613 Yes
2019-07-15 Romano Sarah Chief Financial Officer Sell 19,750 $0.24 $4,669 No
2019-07-15 MANZO MICHAEL P. VP of Engineering Sell 19,750 $0.24 $4,669 No
2019-07-15 Wirostko Barbara Chief Medical Officer Sell 19,463 $0.24 $4,601 No
2019-07-15 FROM STEPHEN President and CEO Sell 127,355 $0.24 $30,107 No
2019-07-15 Mann Brenda VP of Research & Development Sell 19,049 $0.24 $4,503 No
2019-03-29 ARMISTICE CAPITAL, LLC 10%-Owner, Director Buy 549,647 $0.32 $175,216 No
2018-12-11 ARMISTICE CAPITAL, LLC 10%-Owner, Director Buy 100,353 $0.40 $40,316 No
2018-11-16 ARMISTICE CAPITAL, LLC 10%-Owner, Director Buy 360,000 $0.45 $161,395 Yes
2018-05-29 ARMISTICE CAPITAL, LLC 10%-Owner, Director Buy 58,275 $0.57 $33,433 No
2018-05-18 ARMISTICE CAPITAL, LLC 10%-Owner, Director Buy 1,725 $0.56 $959 No
2018-05-14 ARMISTICE CAPITAL, LLC 10%-Owner, Director Buy 15,758 $0.53 $8,417 No
2018-05-11 ARMISTICE CAPITAL, LLC 10%-Owner Buy 177,012 $0.51 $90,992 No
2018-05-08 ARMISTICE CAPITAL, LLC 10%-Owner Buy 137,230 $0.46 $63,472 No
2018-04-26 ARMISTICE CAPITAL, LLC 10%-Owner Buy 165,522 $0.54 $89,266 No
2018-04-20 ARMISTICE CAPITAL, LLC 10%-Owner Buy 2,534,478 $0.49 $1,231,159 No
2018-04-17 ARMISTICE CAPITAL, LLC 10%-Owner Buy 10,479,970 $0.36 $3,740,050 Yes
2017-08-15 Romano Sarah Interim CFO Buy 10,000 $1.00 $10,000 No
2017-08-10 FROM STEPHEN President and CEO Buy 12,500 $1.03 $12,875 No
2017-03-13 Ventech Capital II 10%-Owner Sell 4,419 $2.80 $12,385 No
2017-03-06 GOLDBERG MORTON Director Sell 8,919 $3.00 $26,757 No
2016-09-15 FROM STEPHEN President and CEO Buy 15,000 $1.49 $22,338 No
2016-06-15 GOLDBERG MORTON Director Sell 15,000 $3.16 $47,361 No
2016-06-10 Ventech Capital II 10%-Owner Sell 28,600 $3.04 $86,856 No
2016-06-08 Ventech Capital II 10%-Owner Sell 29,400 $3.25 $95,424 No
2016-06-07 GOLDBERG MORTON Director Sell 10,939 $3.31 $36,203 Yes

Insider Smart

Axsome Therapeutics, Inc (AXSM) - AXSM shows the power of an #allgreen stock, no insider selling, great management great company, if you follow the insiders last year and pick up around $25, the 52 week high is $100+.

Insider Smart

Delta Airlines (DAL) - From an insider's perspective: airlines are the first ones to go under due to the pandemic. A lot of concerns were raised on possible bankruptcy especially amid by the dump from Buffett. However, insiders of Delta were bold enough to buy when Buffett was fear. And Delta is the only airline bought by insiders post-Buffett-dump.